CRISPR Therapeutics Stock Price

0.03 (0.03%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
CRISPR Therapeutics AG CRSP NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-4.55 -4.84% 89.47 86.59 95.56 93.43 94.02 18:59:38
Bid Price Ask Price Spread Spread % News
89.50 89.99 0.49 0.54% 1 -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
20,273 1,558,926 $ 91.02 $ 141,899,484 1,102,887 32.00 - 97.8243
Last Trade Time Type Quantity Stock Price Currency
19:27:33 15 $ 89.50 USD

CRISPR Therapeutics Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 5.54B 61.96M 53.48M $ 289.59M $ 96.64M 0.98 103.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

CRISPR Therapeutics News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical CRSP Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week81.1597.824379.1390.841,626,4638.3210.25%
1 Month62.1397.824358.0076.831,309,70527.3444.0%
3 Months50.8997.824346.8466.531,034,70738.5875.81%
6 Months61.9097.824332.0057.961,006,62127.5744.54%
1 Year48.5097.824332.0057.21902,08940.9784.47%
3 Years15.9997.824315.666148.85836,18073.48459.54%
5 Years15.0097.824311.6348.01694,78474.47496.47%

CRISPR Therapeutics Description

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 is a technology that allows for precise, directed changes to genomic DNA. The company advanced programs target beta-thalassemia and sickle cell disease, two hemoglobinopathies that have a high unmet medical need.

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.